Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Liabilities and Shareholders Equity: 2017-2025

Historic Liabilities and Shareholders Equity for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $1.1 billion.

  • Denali Therapeutics' Liabilities and Shareholders Equity fell 27.40% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 billion, marking a year-over-year decrease of 14.48%. This contributed to the annual value of $1.4 billion for FY2024, which is 19.09% up from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Liabilities and Shareholders Equity is $1.1 billion, which was down 9.49% from $1.2 billion recorded in Q2 2025.
  • Denali Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $1.6 billion during Q1 2024, with a 5-year trough of $1.1 billion in Q3 2025.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $1.3 billion (2023), whereas its average is $1.3 billion.
  • As far as peak fluctuations go, Denali Therapeutics' Liabilities and Shareholders Equity surged by 133.23% in 2021, and later decreased by 27.40% in 2025.
  • Over the past 5 years, Denali Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $1.4 billion in 2021, then grew by 3.99% to $1.5 billion in 2022, then dropped by 20.98% to $1.2 billion in 2023, then grew by 19.09% to $1.4 billion in 2024, then decreased by 27.40% to $1.1 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.1 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.